OBJECTIVE: Hepatitis B virus (HBV) infection is a major global public health problem. Approximately 2 billion people are infected worldwide and more than 350 million of these individuals are chronic carriers of HBV. Approximately 15-40% of infected patients will develop cirrhosis, liver failure, or hepatocellular carcinoma (HCC). Alpha 1 antitrypsin (AAT) deficiency is one of many factors that may be involved in abnormalities such as liver and lung disease, inflammatory joint diseases, and inflammatory eye diseases. In the present study, the role played by AAT in HBV infected individuals is analyzed. METHODS: AAT phenotyping and trypsin inhibitory capacity (TIC) experiments were performed on 281 HBV infected patients who were referred to Tehran and Zahedan Hepatitis Center for a period of 3 years from June 2001 to September 2003. The same tests were performed on 257 individuals who did not suffer from any systemic diseases (control group). The case group was subdivided into three groups: carrier (36.7%), chronic (50.5%), and cirrhotic (12.8%). RESULTS: The results showed that AAT phenotypes, MS, MZ, M(1)Z, and M(1)S, were significantly higher in the HBV group (p<0.01). In addition, there was a significant difference in AAT phenotypes (MS, MZ, and M(1)Z) among inactive carriers and individuals in the chronic and cirrhotic group (p<0.001). CONCLUSIONS: There is a high prevalence of moderate AAT (MS, M(1)S, and MV) and severely deficient (MZ and M(1)Z) phenotypes in Iranian HBV individuals. In addition, AAT deficiency might be a risk factor for infected HBV individuals progressing from the carrier stage to chronic and cirrhotic stages.
OBJECTIVE:Hepatitis B virus (HBV) infection is a major global public health problem. Approximately 2 billion people are infected worldwide and more than 350 million of these individuals are chronic carriers of HBV. Approximately 15-40% of infectedpatients will develop cirrhosis, liver failure, or hepatocellular carcinoma (HCC). Alpha 1 antitrypsin (AAT) deficiency is one of many factors that may be involved in abnormalities such as liver and lung disease, inflammatory joint diseases, and inflammatory eye diseases. In the present study, the role played by AAT in HBV infected individuals is analyzed. METHODS:AAT phenotyping and trypsin inhibitory capacity (TIC) experiments were performed on 281 HBV infectedpatients who were referred to Tehran and Zahedan Hepatitis Center for a period of 3 years from June 2001 to September 2003. The same tests were performed on 257 individuals who did not suffer from any systemic diseases (control group). The case group was subdivided into three groups: carrier (36.7%), chronic (50.5%), and cirrhotic (12.8%). RESULTS: The results showed that AAT phenotypes, MS, MZ, M(1)Z, and M(1)S, were significantly higher in the HBV group (p<0.01). In addition, there was a significant difference in AAT phenotypes (MS, MZ, and M(1)Z) among inactive carriers and individuals in the chronic and cirrhotic group (p<0.001). CONCLUSIONS: There is a high prevalence of moderate AAT (MS, M(1)S, and MV) and severely deficient (MZ and M(1)Z) phenotypes in Iranian HBV individuals. In addition, AAT deficiency might be a risk factor for infected HBV individuals progressing from the carrier stage to chronic and cirrhotic stages.
Authors: David R Nelson; Jeffrey Teckman; Adrian M Di Bisceglie; David A Brenner Journal: Clin Gastroenterol Hepatol Date: 2011-12-23 Impact factor: 11.382
Authors: Erin E Cummings; Linda P O'Reilly; Dale E King; Richard M Silverman; Mark T Miedel; Cliff J Luke; David H Perlmutter; Gary A Silverman; Stephen C Pak Journal: PLoS One Date: 2015-10-29 Impact factor: 3.240
Authors: Mariana Braccialli de Loyola; Thaís Tereza Aguiar Dos Reis; Guilherme Xavier Lyra Malcher de Oliveira; Julys da Fonseca Palmeira; Gustavo A Argañaraz; Enrique R Argañaraz Journal: Rev Med Virol Date: 2020-08-26 Impact factor: 11.043